What is the CVSS score of CVE-2023-27167?

CVE-2023-27167 has a CVSS 3.1 base score of 6.5 (Medium). CVSS vector: CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:N/A:N. EPSS exploitation probability: 7.5%.

Is there a public PoC exploit available for CVE-2023-27167?

Yes, a public proof-of-concept exploit is available for CVE-2023-27167. Prioritise patching immediately. EPSS: 7.5%.

Biostar 2 CVE-2023-27167

MEDIUM

SQL Injection (CWE-89)

2023-03-29 cve@mitre.org

SQLi Biostar 2

6.5

CVSS 3.1 · NVD

Severity by source

NVD PRIMARY

6.5 MEDIUM

AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:N/A:N

Primary rating from NVD · only source for this CVE.

CVSS VectorNVD

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:N/A:N

Attack Vector

Network

Attack Complexity

Low

Privileges Required

Low

User Interaction

None

Scope

Unchanged

Confidentiality

High

Integrity

None

Availability

None

Lifecycle Timeline

CVE Published

Mar 29, 2023 - 17:15 nvd

MEDIUM 6.5

DescriptionNVD

Suprema BioStar 2 v2.8.16 was discovered to contain a SQL injection vulnerability via the values parameter at /users/absence?search_month=1.

AnalysisAI

Suprema BioStar 2 v2.8.16 was discovered to contain a SQL injection vulnerability via the values parameter at /users/absence?search_month=1. Rated medium severity (CVSS 6.5), this vulnerability is remotely exploitable, low attack complexity. Public exploit code available and no vendor patch available.

Technical ContextAI

This vulnerability is classified as SQL Injection (CWE-89), which allows attackers to execute arbitrary SQL commands against the database. Suprema BioStar 2 v2.8.16 was discovered to contain a SQL injection vulnerability via the values parameter at /users/absence?search_month=1. Affected products include: Supremainc Biostar 2.

RemediationAI

No vendor patch is available at time of analysis. Monitor vendor advisories for updates. Use parameterized queries/prepared statements. Never concatenate user input into SQL. Apply least-privilege database permissions.